倾向性评分匹配分析:TCAR、CEA与TFCAS的1年结局比较
基于VQI数据库的倾向性评分匹配分析比较了TCAR、CEA和TFCAS三种颈动脉血运重建术的1年结局。TCAR与CEA的1年同侧卒中或死亡风险无显著差异,TCAR围术期卒中/死亡/心梗风险低于CEA;TCAR围术期卒中或死亡风险低于TFCAS,但1年同侧卒中或死亡风险两者相当。
要点
- TCAR与CEA的1年同侧卒中或死亡风险无显著差异。
- TCAR围术期卒中/死亡/心梗风险低于CEA,主要由心梗风险降低驱动。
- TCAR围术期卒中或死亡风险低于TFCAS,但1年同侧卒中或死亡风险两者相当。
核心结论
- TCAR与CEA或TCAR与TFCAS之间1年同侧卒中或死亡无显著差异。
- TCAR相比TFCAS的优势主要体现在围术期,使其成为手术高危颈动脉狭窄患者的合适微创选择。
研究设计与样本
- 研究基于血管质量倡议(VQI)数据库,纳入2016年9月至2019年12月期间接受TCAR、TFCAS和CEA的患者。
- 采用一对一倾向性评分匹配分析,分别比较TCAR vs CEA和TCAR vs TFCAS。
- 使用Kaplan-Meier生存分析和Cox比例风险回归评估1年同侧卒中或死亡。
主要发现
- TCAR vs CEA匹配4180对,30天卒中、死亡、卒中/死亡无显著差异。
临床怎么用
- TCAR可作为手术高危颈动脉狭窄患者的微创选择,围术期优势明显。
- TCAR与CEA的1年同侧卒中或死亡风险相当,选择需结合患者个体情况。
局限性
- 需要更大样本、更长随访及再狭窄数据的研究来确认TCAR的中长期获益和耐久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Initial studies showed no significant differences in perioperative stroke or death between transcarotid artery revascularization (TCAR) and carotid endarterectomy (CEA) and lower stroke/death rates after TCAR compared with transfemoral carotid artery stenting (TFCAS). This study focuses on the 1-year outcomes of ipsilateral stroke or death after TCAR, CEA, and TFCAS. METHODS: All patients undergoing TCAR, TFCAS, and CEA between September 2016 and December 2019 were identified in the Vascular Quality Initiative (VQI) database. The latest follow-up was September 3, 2020. One-to-one propensity score-matched analysis was performed for patients with available 1-year follow-up data for TCAR vs CEA and for TCAR vs TFCAS. Kaplan-Meier survival and Cox proportional hazard regression analyses were used to evaluate 1-year ipsilateral stroke or death after the three procedures. RESULTS: A total of 41,548 patients underwent CEA, 5725 patients underwent TCAR, and 6064 patients underwent TFCAS during the study period and had recorded 1-year outcomes. The cohorts were well-matched in terms of baseline demographics and comorbidities. Among 4180 TCAR vs CEA matched pairs of patients, there were no significant differences in 30-day stroke, death, and stroke/death. However, TCAR was associated with a lower risk of 30-day stroke/death/myocardial infarction (2.30% vs 3.25%; relative risk, 0.71; 95% confidence interval [CI], 0.55-0.91; P = .008), driven by a lower risk of myocardial infarction (0.55% vs 1.12%; hazard ratio [HR], 0.49; 95% CI, 0.30-0.81; P = .004). At 1 year, no significant difference was observed in the risk of ipsilateral stroke or death (6.49% vs 5.68%; HR, 1.14; 95% CI, 0.95-1.37; P = .157). Among 4036 matched pairs in the TCAR vs TFCAS group, TCAR was also associated with lower risk of perioperative stroke or death compared with TFCAS (1.83% vs 2.55%; HR, 0.72; 95% CI, 0.54-0.96; P = .027). At 1 year, the risks of ipsilateral stroke or death of TCAR and TFCAS were comparable (6.07% vs 7.07%; HR, 0.85; 95% CI, 0.71-1.01; P = .07). Symptomatic status did not modify the association in TCAR vs CEA. However, asymptomatic patients had favorable outcomes with TCAR vs TFCAS at 1 year (HR, 0.78; 95% CI, 0.62-0.98; P = .033). CONCLUSIONS: In this propensity score-matched analysis, no significant differences in ipsilateral stroke/death-free survival were observed between TCAR and CEA or between TCAR and TFCAS. The advantages of TCAR compared with TFCAS seem to be mainly in the perioperative period, which makes it a suitable minimally invasive option for surgically high-risk patients with carotid artery stenosis. Larger studies, with longer follow-up and data on restenosis, are warranted to confirm the mid- and long-term benefits and durability of TCAR.
引用
- Malas MB, Elsayed N, Naazie I, et al. Propensity score-matched analysis of 1-year outcomes of transcarotid revascularization with dynamic flow reversal, carotid endarterectomy, and transfemoral carotid artery stenting. J Vasc Surg. 2021. PMID: 34500027. doi:10.1016/j.jvs.2021.07.242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。